Your browser doesn't support javascript.
loading
Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis.
Priantti, Jonathan N; Vilbert, Maysa; Madeira, Thiago; Moraes, Francisco Cezar A; Hein, Erica C Koch; Saeed, Anwaar; Cavalcante, Ludimila.
Afiliación
  • Priantti JN; School of Medicine, Federal University of Amazonas-UFAM, Manaus 69020-160, AM, Brazil.
  • Vilbert M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
  • Madeira T; Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Moraes FCA; School of Medicine, Federal University of Minas Gerais-UFMG, Belo Horizonte 30130-100, MG, Brazil.
  • Hein ECK; School of Medicine, Federal University of Pará-UFPA, Belém 66075-110, PA, Brazil.
  • Saeed A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
  • Cavalcante L; Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
Cancers (Basel) ; 15(15)2023 Jul 25.
Article en En | MEDLINE | ID: mdl-37568570
ABSTRACT
This systematic review and meta-analysis aims to evaluate the efficacy and safety of rechallenging advanced melanoma patients with BRAFi/MEKi. Seven studies, accounting for 400 patients, were included. Most patients received immunotherapy before the rechallenge, and 79% underwent rechallenge with the combination of BRAFi/MEKi. We found a median progression-free survival of 5 months and overall survival of 9.8 months. The one-year survival rate was 42.63%. Regarding response, ORR was 34% and DCR 65%. There were no new or unexpected safety concerns. Rechallenge with BRAFi/MEKi can improve outcomes in advanced melanoma patients with refractory disease. These findings have significant implications for clinical practice, particularly in the setting of progressive disease in later lines and limited treatment options.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article